Kymera Q2 FY26 net loss narrows to $61.21 million; revenue more than doubles to $65 million - KYMR News | RalliesKymera Q2 FY26 net loss narrows to $61.21 million; revenue more than doubles to $65 million
K
KYMR• Kymera reports narrower quarterly loss and higher collaboration revenue
- Kymera Therapeutics posted a net loss of $61.21 million, narrowing from $76.61 million a year earlier; loss per share improved to $0.62.
- Collaboration revenue more than doubled to $65 million from $11.48 million, driven by $45 million from Gilead’s KT-200 option exercise.
- R&D expenses climbed to $119.48 million from $78.39 million, due to higher STAT6, platform and discovery investment.
- Cash, cash equivalents and investments totaled $1.5 billion; management said this supports runway into 2029.
- KT-621 BROADEN2 Phase 2b AD enrollment finished nearly six months early, shifting topline data to year-end 2026; Phase 3 start targeted by mid-2027.
